07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Micellular docetaxel: Phase I started

Oasmia began an international Phase I trial of IV Docecal in patients. Oasmia Pharmaceutical AB (SSE:OASM; NASDAQ:OASM), Uppsala, Sweden   Product: Micellular docetaxel ( Docecal )   Business: Cancer   Molecular target: Tubulin   Description:...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Oasmia, Orion sales and marketing update

Oasmia granted ORNAV exclusive rights to distribute Paclical micellar paclitaxel ( OAS-PAC-100 ) in Sweden, Denmark, Norway, Finland and Iceland. The water-soluble, solvent-free nanoparticle formulation of paclitaxel is in Phase III testing for ovarian cancer....